Handelsavisen
prelaunch
Companies ›Healthcare ›RHT.AX
RH
RHT.AX — ASX Advanced Medical Equipment & Technology

Rht.Ax

A$0,04
Open in Charts → Attach watcher ⌖
— —
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-16,5 %
ROE
-18,4 %
Net margin
-15,5 %
Debt / equity
0,40
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

ResMed Limited designs, develops, and markets medical devices and cloud-based software solutions for the diagnosis and treatment of sleep-disordered breathing and other chronic diseases.

Business. ResMed Limited designs, develops, and markets medical devices and cloud-based software solutions for the diagnosis and treatment of sleep-disordered breathing and other chronic diseases.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-18,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning RHT.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RHT.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ResMed Limited designs, develops, and markets medical devices and cloud-based software solutions for the diagnosis and treatment of sleep-disordered breathing and other chronic diseases.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    ResMed operates with a debt-to-equity ratio of 0.4 and a current ratio of 1.28, indicating moderate liquidity and a balanced capital structure. However, the company has no cash and equivalents, and its free cash flow is negative at -1.39 million AUD, suggesting potential liquidity constraints. The company's operating cash flow is positive at 1.25 million AUD, which may support short-term obligations.

    Profitability metrics show a return on equity of -18.45% and a return on assets of -9.69%, both significantly below the industry median for Advanced Medical Equipment & Technology. These negative returns indicate that the company is not generating value for shareholders or efficiently utilizing its assets.

    ResMed's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial report. This lack of diversification may expose the company to higher operational and market risks.

    The company's revenue for the latest period is 11.16 million AUD, with no disclosed growth trajectory in the outlook. The absence of a clear growth path and the negative net income of 1.73 million AUD suggest challenges in sustaining profitability.

    Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt and a low dilution risk. The company has not disclosed any dilutive events in the latest filings, and the dilution potential is assessed as low.

    Recent events include the latest actual EPS of 0.00 AUD, indicating no earnings per share for the period. No significant filings or transcripts have been disclosed in the latest data.

    Key takeaways
    • ResMed has a negative return on equity and return on assets, indicating poor profitability.
    • The company has no cash and equivalents, and its free cash flow is negative, suggesting liquidity constraints.
    • Revenue is concentrated in a single business segment with no geographic diversification disclosed.
    • The company's liquidity risk is medium, and dilution risk is low.
    • Recent financial results show no earnings per share for the period.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$0,04
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    A$9.4M
    Net cashⓘ
    -A$3.8M
    Current ratioⓘ
    1.3
    Debt / equityⓘ
    0.4
    ROAⓘ
    -9.7%
    ROEⓘ
    -18.4%
    Cash conversionⓘ
    -72.0%
    CapEx / revenueⓘ
    -5.6%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-16,5 %Below median
    Net Margin-15,5 %Above median
    ROE-18,4 %Below median
    Capex / Rev-5,6 %Below median
    D/E0,40Below median
    Cash Conv-0,72Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • RHT.AX Market data — financials · 2026-05-29
    • Resonance Health Ltd Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RHT.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage